# US 10,308,936 B2 · miR-96-5p inhibitor and a screening method for the inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,936 B2
- Document ID: US10308936B2
- Status: Granted
- Kind: B2
- Application number: 15/486,648
- Filed: 2017-04-13
- Published: 2017-08-03
- Granted: 2019-06-04
- Earliest claimed: 2014-10-08
- Assignees: Teikyo University
- Applicants: Teikyo University
- Inventors: Toshio Nakaki; Chisato Kinoshita
- Web page: https://patentgrep.com/patent/US10308936B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- G01N 33/5023: {on expression patterns}
- G01N 33/5058: {Neurological cells}
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/10: in screening processes
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides novel medical means to facilitate glutathione (GSH) synthesis in the brain. These means are miR-96-5p inhibitor increasing GSH expression in the brain and a pharmaceutical composition comprising the miR-96-5p inhibitor and having a preventive and/or therapeutic performance to a disease caused by decrease of GSH amount or depression of GSH activity.

## Claims

### Claim 1

A method for increasing an expression of glutathione (GSH) in the brain of a subject by administering a miRNA-96-5p inhibitor into the brain of the subject, wherein the miRNA-96-5p inhibitor is an oligonucleotide at least partially complementary to the nucleotide sequence of SEQ ID NO:1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the miRNA-96-5p inhibitor is an antisense oligonucleotide for the sequence of SEQ ID NO:1.

### Claim 3

A method for treating a neurodegenerative disease caused by decrease of glutathione (GSH) amount or depression of GSH activity, which comprises administrating a miRNA-96-5p inhibitor into the brain of a subject, wherein the miRNA-96-5p inhibitor is an oligonucleotide at least partially complementary to the nucleotide sequence of SEQ ID NO:1.

### Claim 4 (depends on 3)

The method of claim 3, wherein the miRNA-96-5p inhibitor is an antisense oligonucleotide for the sequence of SEQ ID NO:1.

### Claim 5 (depends on 3)

The method of claim 3, the disease is a neurodegenerative disease caused by an oxidative stress in the brain.